BTIG Keeps Buy Rating on CareDx and Natera, Lifts Natera Target
BTIG kept its Buy rating on CareDx and Natera and raised its Natera price target to $430 from $320. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reported that BTIG analysts maintained their Buy recommendation on CareDx shares. For Natera, BTIG also kept a Buy rating and lifted its price target from $320 to $430 per share.
The rating actions for both companies were compiled from Benzinga data.
why it matters
Single-analyst rating moves like these usually affect only the stocks of the companies involved and rarely shift the broader market. For CDNA and NTRA investors, it signals that BTIG still holds a positive view, though it is not a standalone price driver.
tags
instruments
sources
- CareDx Is Maintained at Buy by BTIG — Dow Jones Newswires, 27 October 2026 at 17:01 UTC
- Natera Is Maintained at Buy by BTIG — Dow Jones Newswires, 27 October 2026 at 16:58 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗